Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.
Pembrolizumab is used to treat various types of cancer, including melanoma, non-small cell lung cancer and head and neck squamous cell cancer.
AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...
Merck (NYSE: MRK) closed Tuesday's session down 0.87% at $128.26, breaking a six-session winning streak. The stock had gained 13.62% over the preceding six trading sessions, outperforming the S&P 500, ...
Sen. Maggie Hassan is pressing pharmaceutical giant Merck over access and cost issues around one of its most popular and best ...
Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an increasingly intertwined human-machine model moves closer to adoption in real-world ...
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 ...
On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two ...
Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald ...
In a notice flagging a series of problems with a clinical trial, the journal Nature Medicine said its editors “no longer have ...
SurvivorNet on MSN
New data and FDA approval brings hope for metastatic triple-negative breast cancer
Two major studies are looking at moving sacituzumab govitecan earlier for metastatic triple-negative breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results